[Skip to Content]
[Skip to Content Landing]
Citations 0
The Pediatric Forum
April 5, 2010

Selective Serotonin Reuptake Inhibitor Exposure in Pregnancy and Neonatal Adverse Events

Author Affiliations

Author Affiliations: Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel (Dr Dubnov-Raz); Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada (Drs Koren and Finkelstein); and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts (Dr Finkelstein).

Arch Pediatr Adolesc Med. 2010;164(4):394-395. doi:10.1001/archpediatrics.2010.34

We read with great interest the article by Lund et al1 on selective serotonin reuptake inhibitor (SSRI) exposure in utero and pregnancy outcomes. This study, and several previous ones, demonstrated the effects of SSRI use during pregnancy on duration, birth weight, neonatal adaptation, and respiratory effects. Lund et al identified an elevated risk for low Apgar scores and neonatal intensive care unit admissions among SSRI-exposed neonates, which were not explained by the underlying psychiatric condition.

First Page Preview View Large
First page PDF preview
First page PDF preview
×